Methods:
Rats at 1-month-old were treated with an EGFR-specific small molecule inhibitor, gefitinib, for 7 days. Long bones were harvested to analyze their growth plate structure and gene expression using immunostaining, in situ hybridization and histological methods. RNA and protein were extracted from growth plate cartilage isolated under dissection microscope for quantitative RT-PCR, zymography and Western blot experiments. Rat primary chondrocytes, derived from the distal femoral and proximal tibial condyles of newborn pups, were cultured and treated by TGFα, an EGFR ligand, to examine the effects of EGFR signaling on chondrogenic gene expression in vitro. A mouse model of cartilage-specific EGFR inactivation was generated for analyzing the postnatal growth plate development. All data were analyzed by independent Student's t-test and are presented as mean ± sem. Animal number per group varied from 3-6.
Results: After treated with gefitinib for one week, rats developed profound changes in the growth plate cartilage in both femurs and tibiae characterized by epiphyseal growth plate thickening and accumulation of hypertrophic chondrocytes (Fig. 1) . In these animals, we observed an overall 2.0-fold increase in the tibial growth plate length. This was mainly due to a striking increase in the length of hypertrophic zone (2.3-fold). Immunostaining for Ki67, a marker for replicating cells, and p57, a marker for cell cycle exit, as well as in situ hybridization for Col10a1, a hypertrophic zone marker, further confirmed that the hypertropic zone, but not the proliferative zone, was enlarged by gefitinib. These changes are reversible since the growth plate returned to normal one week after withdrawal of gefitinib. The primary spongiosa of metaphyseal bone underneath the growth plate is derived directly from the hypertrophic zone through a bone modeling process. Compared to vehicle group, gefitinib-treated rats had shorter bone spicules with irregular shapes and more cartilage remnants, providing the first hint that gefitinib delays the conversion of cartilage matrix into bone matrix.
Immunostaining demonstrated that growth plate chondrocytes express EGFR but endothelial cells and osteoclasts have low to no expression. Osteoclasts at the chondro-osseous junction (COJ) play an essential role in endochondral ossification through secretion of various proteases to digest cartilage matrix for vascular invasion and deposition of bone matrix. Interestingly, we observed a significant decrease in the number of TRAP-positive cells located just below the last row of terminally differentiated chondrocytes in the gefitinib group ( Fig. 2A) . However, the number of osteoclasts in the primary spongiosa was not changed, indicating that osteoclasts are not direct targets for gefitinib. Further qRT-PCR revealed a 3.6-fold decrease in the expression of RANKL, a major determinant for osteoclastogenesis, in gefitinib-treated growth plate (Fig. 2B) , demonstrating that EGFR signaling is required for chondrocytes to support osteoclastogenesis at the COJ. Several matrix metalloproteinases (MMPs), such as MMP9, 13 and 14, are expressed at high levels in bone and cartilage and are indispensable for the cleavage of cartilage matrix and remodeling of cartilage into bone. We found that the mRNA and protein levels of these MMPs were significantly suppressed 3-to 4-fold in the growth plate of gefitinib-treated rats ( Fig. 3A and B) . Moreover, gelatin zymography showed that the activity of MMP9, in both pro (a) and mature (b) forms, was attenuated (Fig. 3C) . In situ hybridization revealed that MMP13 gene expression in the terminally differentiated chondrocytes was dramatically suppressed by gefitinib (Fig. 3D) . Further analyses using polarized light microscope, immunostaining for intact and degraded type II collagen products revealed that cartilage matrix degradation is blunted by EGFR inhibition. In vitro, activation of EGFR by TGFα strongly stimulated RANKL, MMP9, 13 and 14 expression in primary chondrocytes, demonstrating that EGFR signaling directly regulates these genes in chondrocytes.
Fig 3. Gefitinib inhibits MMP expression in the growth plate.
To exclude the possibility that gefitinib might act on cells other than chondrocytes to affect growth plate development, we generated a chondrocyte-specific EGFR inactivation mice (Col2a1-Cre Egfr Wa5/flox , Wa5 is an Egfr dominant negative allele). Analyzing their long bone growth plate at P5 revealed that, while the Wa5 itself (Egfr Wa5/f mice) modestly increased the length of the hypertrophic zone (1.3-fold),
Col2a1-Cre Egfr
Wa5/flox dramatically expanded the hypertrophic zone to 2.0-fold compared to Egfr +/f mice, demonstrating that chondrogenic EGFR activity is essential for endochodral ossification.
Discussion: Our data demonstrate that EGFR signaling regulates cartilage matrix degradation directly by stimulating growth plate chondrocytes to express MMPs and indirectly by up-regulation of RANKL in cartilage to support osteoclastogenesis at the COJ. These two mechanisms might be complementarily interplayed. Hence, we conclude that EGFR signaling has a critical function in the remodeling of growth plate cartilage extracellular matrix into bone during endochondral ossification.
Significance: Our project investigates the role of a novel growth factor signaling in regulating growth plate development and sheds new light on studying the mechanisms and treatments of diseases associated with growth cartilage defects, such as chondrodysplasia, retarded growth and reduced final height.
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